Hexa-lipopolysaccharide (hexa-LPS) production

Lipopolysaccharide is a fat-and-sugar molecule on the outer surface of gram-negative bacteria. It's usually shortened to LPS and is often called endotoxin. Different forms can have very different effects on human immune cells. This stool result estimates your gut microbiome's genetic capacity to produce a form whose anchor, lipid A, carries six fatty tails. That form is called hexa-acylated LPS, and it can strongly stimulate those immune cells.

This is an exploratory measurement. How lipid A interacts with immune receptors is well established in laboratory research, but that biology doesn't validate this stool estimate. Its accuracy, its ability to predict disease, and its value for guiding treatment in an individual remain unproven.

What the Number Represents

Shotgun metagenomic sequencing reads microbial DNA in your stool. From that DNA, the result estimates how much of your gut community has the genetic machinery linked to making six-tailed LPS. Actual production, release into the gut, and exposure elsewhere in your body are separate questions.

Sequencing results like this are proportional. A larger share can reflect more potential producers, fewer other microbes, or both. It isn't an absolute bacterial count or a chemical concentration of LPS. A result compared with a reference population describes a difference in microbial capacity; that difference alone doesn't establish illness.

Why the Fatty Tails Matter

Lipid A anchors LPS in the bacterial outer membrane and carries its fatty-acid tails. Human immune cells recognize it through a receptor complex called TLR4/MD-2. The six-tailed structure made by E. coli strongly activates this complex. Many four- and five-tailed structures stimulate it less, and some inhibit its activation in laboratory experiments.

Tail number is only part of the chemistry. Tail length, arrangement, and other chemical attachments also affect the response. Six-tailed structures aren't all equally inflammatory, and five-tailed structures aren't uniformly inactive: some five-tailed forms activate human TLR4 in experiments. These distinctions come largely from structural studies and experiments using purified molecules and cultured cells.

E. coli is the classic six-tail producer. Klebsiella and Shigella can also make six-tailed lipid A, but the structure varies by strain and growth conditions; one study of a Shigella strain found a mixture dominated by forms with fewer tails. Many Bacteroides species make less strongly stimulating forms. In E. coli, the enzymes LpxL and LpxM add the fifth and sixth tails. Other bacteria can use different enzymes or modify the structure after assembly, so a species name or one gene doesn't fully describe the final molecule.

Production Potential and Producer Ratios

Some research compares predicted six-tailed producers with predicted five-tailed producers. That ratio is a different measurement from this test's six-tailed production potential. It can rise because the six-tailed group increases or because the five-tailed group decreases. Research has not established that the ratio is a better clinical predictor than production potential alone.

The Human Evidence on Immune Activation

An exploratory study in adults with HIV used 16S sequencing to identify bacterial groups and infer their LPS-producing capacity. That method differs from this test's shotgun metagenomic analysis, and the producer categories were inferred rather than confirmed by chemically measuring lipid A. Predicted five-tailed producers outnumbered six-tailed producers by about 25 to 1 in the main cohort. A higher six-to-five ratio tracked with higher blood neopterin and a higher kynurenine-to-tryptophan ratio. These blood measures reflect immune activation and tryptophan breakdown. The associations were cross-sectional and don't establish cause and effect or a healthy balance for the general population.

Stool metagenomic research in Crohn's disease found predicted six-tailed LPS producers enriched in some patients' microbiomes, with differences between distinct community types. Inflammation can change the gut environment and its bacterial inhabitants, so this association doesn't establish which change came first.

Gut Capacity and Blood Exposure Are Different

LPS is normally present in the gut. Its effects depend on its structure, location, amount, and the body's response. Increased intestinal permeability can allow more bacterial material to cross the gut lining. Cell and rodent experiments show LPS can also pass through intestinal cells and travel with dietary fat as it's absorbed. How much these routes contribute in people, and whether the rise in blood LPS after fatty meals matters for inflammation, remains uncertain. A damaged or visibly inflamed barrier isn't the only possible route.

Blood exposure also depends on how LPS binds to circulating proteins and how it is neutralized and cleared, including by the liver. The stool production estimate captures none of these processes. Blood antibodies against LPS or zonulin are indirect research measures and cannot establish that six-tailed LPS from your gut is entering your circulation.

Cardiometabolic Associations

A study of stool metagenomes from European women found genes involved in LPS synthesis, including LpxM, enriched in untreated type 2 diabetes. This supports an association between diabetes and bacterial production capacity. It doesn't establish that these genes caused diabetes or that lowering their abundance would improve blood sugar.

A separate study of 50 older postmenopausal women, selected from the extremes of fat around the abdominal organs, linked more of that fat with more potentially inflammatory bacterial species and higher blood LPS-binding protein and certain antibacterial antibodies. These blood measurements are different from stool production potential. The study's experiments involving LPS administration and metabolic improvements were performed in mice.

Research in people with coronary artery disease found higher stool endotoxin activity. That activity was measured with a test based on horseshoe crab blood cells. Its reaction to LPS isn't the same as the potency of LPS on human immune cells or the amount of LPS present, and it assesses a different feature from this DNA-based production estimate. The accompanying evidence that Bacteroides supplementation reduced atherosclerosis came from mice.

A Higher Result Isn't Universally Harmful

Immune stimulation can have different consequences in different settings. An analysis of stool metagenomes from 112 people with melanoma found more genetic capacity for six-tailed LPS production among those who responded to anti-PD-1 immunotherapy. Supporting experiments showed a role for this immune stimulation in mouse tumor models. The human findings were observational and haven't established a clinical test for choosing cancer treatment, but they argue against assuming that less six-tailed LPS is always better.

What Long-Term Studies Have Measured

The FINRISK study followed 7,043 Finnish adults for a median of about 18 years, during which 1,092 participants had a fracture. Stool microbial pathways related to LPS synthesis and a greater relative abundance of Proteobacteria were associated with fracture risk. These were broader microbial measurements; the study did not establish this six-tailed production estimate as a fracture predictor.

Other prospective studies measured LPS or related proteins in blood. In 912 people with atrial fibrillation, those in the highest third of serum LPS had about an 80 percent higher hazard of major cardiovascular events than those in the lowest third. In the adjusted analysis, LPS analyzed as a continuous measure remained associated with events. Neither analysis measured stool hexa-LPS production potential.

Results for blood proteins involved in recognizing and handling LPS have varied. In the Nurses' Health Study II and Health Professionals Follow-up Study, LPS-binding protein wasn't associated with coronary heart disease in either sex. Soluble CD14 was associated with coronary disease in women, but that association was no longer statistically significant after further adjustment for CRP and the total-to-HDL cholesterol ratio.

These studies examine different molecules, populations, and outcomes. They provide context for research on endotoxin exposure, but their risk estimates cannot be applied to your stool production result.

When Results Can Be Misleading

Gut microbial populations vary over time. Daily quantitative profiling in a small group of people found the absolute abundance of some bacterial groups changing by as much as a hundredfold over several weeks, with stool moisture contributing to that variation. Other metagenomic studies found broad community composition and genetic functional potential comparatively stable. Neither finding establishes how much this particular production estimate should vary within you.

• Genetic capacity versus activity: DNA indicates what microbes may be able to produce. It doesn't establish whether those genes are active or how much LPS is released.
• Relative abundance: The reported share can change when other members of the microbial community change, even without an increase in the absolute number of six-tailed producers.
• Stool consistency and recent exposures: Bowel transit, diarrhea, diet, antibiotics, and other medications can alter the microbial profile. A change need not represent a lasting change in inflammation.
• Collection and analysis: Sample preservation, DNA extraction, sequencing depth, and reference databases can affect the estimate, especially for less abundant organisms. Results from different methods or laboratories aren't automatically interchangeable.
• Location: Stool mainly represents microbes shed from the lower intestine. It doesn't fully describe microbes attached to the intestinal lining or those in the small intestine.
• Clinical interpretation: Neither a larger production estimate nor a change over time has been validated as proof of tissue injury, increased intestinal permeability, or treatment benefit.